Polycythemia Vera Market
The Polycythemia Vera market is witnessing significant transformation driven by evolving therapeutic innovations, expanding diagnosed populations, and a growing pipeline of targeted agents. The total Polycythemia Vera market size across the 7 Major Markets (7MM) is approximately ~USD 2,000 million in 2025 and is projected to increase steadily during the forecast period (2026–2036).
In 2025, the United States represented the largest share among the 7MM, accounting for approximately ~USD 1,500 million – a figure expected to rise further by 2036, fueled by the launch of emerging therapies and a growing diagnosed prevalent population of Polycythemia Vera.
Download the comprehensive Polycythemia Vera market report covering epidemiology, drug uptake, and competitive intelligence now.
Polycythemia Vera Therapies
The current and emerging therapeutic landscape for Polycythemia Vera includes the following approved and investigational agents: Ruxolitinib (JAKAFI/JAKAVI), Ropeginterferon alfa-2b (BESREMi), Rusfertide, Bomedemstat, Givinostat (DUVYZAT), Sapablursen (TMPRSS6), Divesiran (SLN124), PPMX-T003, 9MW3011/DISC-3405, and Others.
Polycythemia Vera Overview
Polycythemia Vera is a rare, chronic myeloproliferative neoplasm (MPN) characterized by a progressive increase in red blood cells (RBCs) in the bloodstream, accompanied by elevated white blood cells (WBCs) and platelets in affected individuals. Among all MPNs, Polycythemia Vera is the most common and the only condition associated with an absolute increase in RBC production.
The disease predominantly affects the elderly population, placing patients at heightened risk of thrombotic events and other comorbidities. The chronic, progressive nature of the disease, combined with limited curative options, underscores the urgent need for continued innovation across the Polycythemia Vera market research landscape.
Polycythemia Vera Diagnosis
Diagnosis of Polycythemia Vera is based on results from tests assessing elevations in blood counts and the presence of molecular mutations associated with the disease. The initial evaluation includes a focused clinical history, physical examination, hematocrit concentration, and count of RBC, WBC, and platelets, along with serum EPO levels and cytogenetic abnormality testing. The patient journey typically begins with a referral to a hematologist.
Most markets follow WHO diagnostic criteria based on a composite of clinical and laboratory features, including JAK2 mutation status and serum erythropoietin levels. However, real-world geographic variation exists – European organizations such as the British Society for Haematology have cited studies reporting high rates of failure to reach a histological diagnosis in Polycythemia Vera patients, reflecting meaningful differences in diagnostic practices across regions.
Polycythemia Vera Treatment
Based on real-world treatment pattern analysis, patients with Polycythemia Vera receive myelosuppressive therapies that suppress the formation of blood cells by the marrow. Hydroxyurea is the most commonly used chemotherapy agent, alongside busulfan. Other agents such as chlorambucil and radioactive phosphorus have also been used. JAKAFI and BESREMi are the two FDA-approved drugs for treating Polycythemia Vera – JAKAFI in the second line and BESREMi across both first and second lines. Low-dose aspirin and phlebotomy remain recommended first-line options for patients at low risk of thrombotic events.
Despite available options, medication adherence remains a persistent challenge. Patients prescribed injectable cytoreductive therapies demonstrate lower adherence than those on oral formulations, driven by polypharmacy burden, side effects, cost concerns, and complex dosing regimens. Approximately 30% of hydroxyurea-treated patients become resistant or intolerant over time, highlighting a critical gap that continues to drive unmet need within the broader Polycythemia Vera market insight framework.
Polycythemia Vera Unmet Needs
The unmet needs of Polycythemia Vera outline critical gaps between the current state of patient care and the ideal management of the disease. Key unmet needs include:
- Poor sustained hematocrit (Hct) control – ongoing disease burden persists despite available therapies
- Delayed diagnosis – despite established WHO criteria and clear treatment triggers
- Psychosocial and access challenges – linked to the disease’s rarity and low clinical awareness
- Deteriorating quality of life – driven by treatment burden, side effects, and symptom persistence
- Limited third-line options – patients failing first- and second-line therapies have few viable alternatives
Polycythemia Vera Epidemiology
Key findings from the Polycythemia Vera epidemiological analysis and forecast:
- The United States contributed the largest prevalent population, accounting for ~55% of 7MM in 2025; EU4 and the UK contributed ~30%, and Japan ~15%
- Total prevalent cases in the United States reached approximately ~158,700 in 2025
- Among EU4 and the UK, Germany recorded the highest number of cases, while the UK recorded the lowest in 2025
- In the US, approximately ~63,000 cases were asymptomatic and ~95,000 cases were symptomatic in 2025; prevalence is projected to rise through 2036
- In Japan, the highest burden fell in the 65–74 age group (~6,000 cases), while the 0–34 age group was least affected (~800 cases)
- Across 7MM, approximately ~60% of prevalent patients are male, with females accounting for the remaining ~40%
Approved Therapies for Polycythemia Vera
- Ruxolitinib (JAKAFI/JAKAVI) – Incyte/Novartis
JAKAFI/JAKAVI is an oral JAK1/JAK2 tyrosine kinase inhibitor approved for adult Polycythemia Vera patients resistant to or intolerant of hydroxyurea. It received FDA approval as a second-line therapy in December 2014, followed by EU and Japan approvals in 2015. At the December 2024 ASH Annual Meeting, novel research highlighted the long-term safety and efficacy of ruxolitinib, with poster presentations demonstrating its superiority over hydroxyurea and its role in reducing corticosteroid dependence in Polycythemia Vera patients.
Leading Polycythemia Vera Companies
The leading companies developing therapies for Polycythemia Vera include:
- Incyte / Novartis
- PharmaEssentia / AOP Orphan Pharmaceuticals
- Protagonist Therapeutics / Takeda Pharmaceuticals
- Merck (Imago BioSciences)
- Italfarmaco
- Ionis Pharmaceuticals / Ono Pharmaceutical
- Silence Therapeutics
- Perseus Proteomics
- AbbVie
- Johnson & Johnson Innovative Medicine
- Mabwell (Shanghai) Bioscience / Disc Medicine
- GluBio Therapeutics, and others.
Polycythemia Vera Drug Updates
Recent developments shaping Polycythemia Vera market trends include:
- Incyte announced at J.P. Morgan Healthcare Conference 2026 that ruxolitinib extended-release (XR) – a once-daily formulation for Polycythemia Vera – is expected to receive regulatory approval and launch around mid-2026
- Ionis Pharmaceuticals disclosed plans to initiate a Phase III clinical trial of sapablursen for Polycythemia Vera in 2026
- Vanda Pharmaceuticals announced in August 2025 that the FDA granted Orphan Drug Designation for VGT-1849B, a selective peptide nucleic acid-based JAK2 inhibitor for Polycythemia Vera
- Italfarmaco anticipates the launch of DUVYZAT (givinostat) in 2027 for the treatment of Polycythemia Vera
Polycythemia Vera Market Outlook
The Polycythemia Vera treatment landscape is entering a new era as novel agents challenge established standards of care. Until the approvals of BESREMi and JAKAFI, the market was dominated by legacy agents – hydroxyurea, phlebotomy, and second-generation interferons. While BESREMi spans both first- and second-line settings and JAKAFI is approved in the second line, third-line options remain critically limited, representing one of the most significant gaps in the current treatment paradigm.
The forecast model segments the market by therapeutic class, covering JAK inhibitors, interferons, hepcidin mimetics, TMPRSS6 inhibitors, CK1α activators, BCL-2 inhibitors, and LSD1 inhibitors. A rich pipeline – including rusfertide (Protagonist Therapeutics/Takeda), bomedemstat (Merck), givinostat (Italfarmaco), sapablursen (Ionis/Ono), divesiran (Silence Therapeutics), PPMX-T003 (Perseus Proteomics), and DISC-3405 (Disc Medicine) – is progressing through various stages of clinical development, with each candidate aiming to address the persistent unmet needs left by existing approved therapies.
Explore the full Polycythemia Vera market landscape, pipeline analysis, and 10-year forecast for Polycythemia Vera today.
Polycythemia Vera Drug Uptake
This section focuses on the projected uptake rates of potential Polycythemia Vera drugs expected to launch during 2022–2036. For rusfertide, despite the FDA rescinding its Breakthrough Designation, uptake is projected to be medium-fast, with a probability-adjusted peak share of ~5.7% across first and second lines and an estimated 7 years to peak from launch – underpinned by a differentiated safety and efficacy profile relative to existing agents. Uptake modeling across all pipeline therapies accounts for line of therapy, clinical differentiation, pricing dynamics, and competitive entry timelines, with new launches expected to progressively shift market share away from legacy agents, particularly among hydroxyurea-resistant or intolerant patients.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
